Compare Enveric Biosciences Inc (ENVB) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs TJX Companies Inc — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while TJX Companies Inc trades at $154.6 (market cap $166.78B). The key difference: TJX Companies Inc is far larger — about 31349.6× Enveric Biosciences Inc's market cap, and TJX Companies Inc pays a 1.27% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | TJX | |
|---|---|---|
Market Cap | $5.32M | $166.78B |
Sector | Health | Consumer Cyclical |
52-Week High | $17.40 | $168.41 |
52-Week Low | $1.28 | $121.35 |
Enterprise Value | $408.82K | $175.38B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
TJX Companies (TJX) trades at $150.35, down 0.12% on the day, showing resilience amid broader market volatility. The stock exhibits a bearish technical signal with moving averages indicating selling pressure, though oscillators remain neutral. Fundamentally, TJX demonstrates strong profitability with a 9.4% net income margin and exceptional 61.25% ROE, supported by consistent earnings beats in recent quarters. Revenue growth continues steadily, reaching $56.36B in 2025 with improving margins. Recent news highlights TJX as a defensive retail play during economic uncertainty, with expansion into international markets providing growth catalysts.
TJX presents a compelling growth story with robust fundamentals and strong analyst support (88% buy ratings), though current valuation appears elevated at 29.37 P/E. The company's off-price retail model benefits from inflationary environments, but execution risks include international expansion challenges and competitive pressures. With a consensus price target of $181.80 offering 21% upside potential, the stock represents a quality retail holding for long-term investors willing to accept premium valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
